Curidium is a personalized medicine company identifying targeted medicines and companion diagnostics to treat patients more effectively.
Curidium’s initial focus on diseases of the Central Nervous System has resulted in the identification of a blood diagnostic test, PsychINDx™, which classifies patients with schizophrenia/bipolar disorder into four subgroups. PsychINDx™ may have the potential to improve the treatment of patients with schizophrenia/bipolar disorder.
Many chronic human diseases are heterogeneous and their patient populations consist of mixed subgroups. Through the use of its proprietary analysis tool, Homomatrix®, Curidium aims to reveal different patient subgroups characterized by distinct underlying disease mechanisms potentially leading to the identification of:
- Diagnostics for better identification and treatment within heterogeneous disease populations.
- Improved therapies identified through novel drug targets.
- Personalized medicines using companion diagnostics and targeted treatments.
Curidium aims to continue to use this approach to improve patient treatments in a variety of therapeutic areas.
